Cargando…
Pirfenidone as a novel cardiac protective treatment
Myocardial fibrosis is a common feature of several heart diseases. The progressive deposition of extracellular matrix due to a persistent injury to cardiomyocytes may trigger a vicious cycle that leads to persistent structural and functional alterations of the myocardium. Some drugs (like renin–angi...
Autores principales: | Aimo, Alberto, Spitaleri, Giosafat, Panichella, Giorgia, Lupón, Josep, Emdin, Michele, Bayes-Genis, Antoni |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898227/ https://www.ncbi.nlm.nih.gov/pubmed/34671871 http://dx.doi.org/10.1007/s10741-021-10175-w |
Ejemplares similares
-
Pirfenidone for Idiopathic Pulmonary Fibrosis and Beyond
por: Aimo, Alberto, et al.
Publicado: (2022) -
Cardiac protection by pirfenidone after myocardial infarction: a bioinformatic analysis
por: Aimo, Alberto, et al.
Publicado: (2022) -
Management of heart failure with preserved ejection fraction: from neurohormonal antagonists to empagliflozin
por: Aimo, Alberto, et al.
Publicado: (2022) -
Gender-Related Differences in Heart Failure Biomarkers
por: Cediel, Germán, et al.
Publicado: (2021) -
Amyloid seeding as a disease mechanism and treatment target in transthyretin cardiac amyloidosis
por: Morfino, Paolo, et al.
Publicado: (2022)